FAWZY BASTA: Open Payments
NPI 1043394505 · NORTHRIDGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$32,686 in 187 payments from 19 companies in 2025. Trend: 2023 $78,135 · 2024 $74,510 · 2025 $32,686
Speaker / faculty: $21,125Consulting: $5,200Food & beverage: $4,796Travel & lodging: $1,438Education: $127
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 35 | $17,356 |
| ACADIA Pharmaceuticals Inc | 15 | $12,140 |
| ABBVIE INC. | 24 | $667 |
| Teva Pharmaceuticals USA, Inc. | 30 | $549 |
| E.R. Squibb & Sons, L.L.C. | 23 | $522 |
| Vanda Pharmaceuticals Inc. | 10 | $318 |
| Alpha Cognition USA, Inc. | 7 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $227 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Bausch Health US, LLC | 8 | $149 |
Products named: INGREZZA, NUPLAZID, VRAYLAR, COBENFY, FANAPT, AUSTEDO XR, Zunveyl, CAPLYTA.
Industry payments across CA — which companies pay providers there.
